Leviticus Cardio

Company Overview

Snapshot

Founded in February 2008 by Michael Zilbershlag, Yigal Kassif, and Moshe Levy, Leviticus Cardio operates with 1–10 employees. The company secured $5.77 million across 5 funding rounds from 2 investors. In January 2019, Leviticus Cardio and Jarvik Heart were awarded an R&D grant from the BIRD Foundation.

Business overview

Leviticus Cardio develops a wireless system designed to power implanted ventricular assist devices (VADs), aiming to eliminate complications associated with traditional drive lines. The company's core technology, Coplanar Energy Transfer (CET), is compatible with various commercial VADs, utilizing an implanted receiver coil and an external transmitter coil for inductive electromagnetic power transfer. This solution serves the cardiology and cardiovascular markets, operating within the Health Tech & Life Sciences sector, specifically focusing on medical devices and treatments.

Strategic signal

In March 2026, Leviticus Cardio ceased operations, indicating a significant shift in its corporate trajectory. This cessation of activity signals to investors and innovation teams the conclusion of the company's efforts in developing its wireless VAD solution.

Company Intelligence Q&A

What is the current operational status of Leviticus Cardio?

Leviticus Cardio is currently non-active, having ceased operations in March 2026.

When was Leviticus Cardio founded and by whom?

Leviticus Cardio was founded in February 2008 by Michael Zilbershlag, Yigal Kassif, and Moshe Levy.

What was a significant funding event for Leviticus Cardio?

In January 2019, Leviticus Cardio and Jarvik Heart were awarded an R&D grant from the BIRD Foundation.

What was a key clinical development for the company?

In February 2019, the company's wireless heart pump technology was implanted in a patient for the first time.

What was the total capital raised by Leviticus Cardio?

Leviticus Cardio raised a total of $5.77 million across 5 funding rounds.